The Pharmacovigilance in the CIS, EAEU

---

The Pharmacovigilance in the CIS, EAEU: Regulatory Frameworks, Challenges, and Future Directions

Pharmacovigilance (PV) is essential to ensuring the safety of medicinal products after they are introduced to the market, as it helps identify adverse drug reactions (ADRs) and other safety issues that may not have been observed in pre-market clinical trials. The Commonwealth of Independent States (CIS), Eurasian Economic Union (EAEU), and countries like Georgia, Ukraine have seen significant developments in their pharmacovigilance systems in recent years. However, these countries face unique challenges in terms of regulatory harmonization, resource allocation, and data reporting. This article provides an overview of the pharmacovigilance systems in the CIS/EAEU, Georgia, and Ukraine, highlighting the regulatory frameworks, key challenges, and opportunities for further improvement. Through an analysis of available literature, the paper discusses the ongoing efforts to enhance pharmacovigilance practices and proposes potential solutions for strengthening drug safety monitoring in these regions.

---

---

1. Introduction

Pharmacovigilance, as defined by the World Health Organization (WHO), is the science and activities relating to the detection, assessment, understanding, and prevention of adverse drug reactions (ADRs) or any other drug-related problems (WHO, 2002). The importance of pharmacovigilance cannot be overstated, as it helps safeguard public health by detecting harmful effects of drugs once they are in widespread use. While many high-income countries have well-established pharmacovigilance systems, low- and middle-income countries, particularly those in the CIS and EAEU regions, face considerable challenges in establishing robust drug safety monitoring frameworks.

The CIS includes several former Soviet republics, including Russia, Kazakhstan, Belarus, and others, while the EAEU is a political and economic union comprising Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Russia. Azerbaijan, Georgia, and Ukraine are located in the Caucasus and Eastern European region and have distinct yet increasingly harmonized pharmacovigilance systems. This article reviews the pharmacovigilance landscape in these countries, examining regulatory developments, key challenges, and future directions for improving drug safety monitoring.

2. Pharmacovigilance Regulatory Frameworks

2.1 The CIS and EAEU

In the CIS, several countries have developed pharmacovigilance systems in alignment with international best practices, but regulatory frameworks vary significantly in their maturity. The Eurasian Economic Union (EAEU), which was established to foster economic and political integration, includes five member states — Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Russia — and plays a crucial role in harmonizing pharmacovigilance regulations.

2.2 Georgia, and Ukraine

These countries have separate regulatory frameworks from the EAEU, but they have been increasingly aligning their pharmacovigilance practices with European Union (EU) standards, particularly Ukraine, which has formalized its pharmacovigilance system through its association with the EU.

3. The Pharmacovigilance in the CIS, EAEU: Key Challenges

While the pharmacovigilance systems in the CIS/EAEU, Georgia, and Ukraine have made significant progress, several challenges persist:

1. Underreporting of ADRs: Underreporting remains a significant problem in all these countries. Healthcare professionals may not always report ADRs due to lack of training, awareness, or resources. Additionally, there is often a lack of incentive structures to encourage reporting.
2. Regulatory Gaps: Although the EAEU aims to harmonize pharmacovigilance regulations, gaps remain in the implementation and enforcement of pharmacovigilance laws across its member states. Non-EAEU countries like Azerbaijan, Georgia, and Ukraine face additional challenges in aligning their systems with EU standards.
3. Lack of Resources and Infrastructure: In many of these countries, insufficient funding and a shortage of trained personnel hinder the effective implementation of pharmacovigilance activities. This is particularly evident in remote and rural areas where ADR reporting is less frequent.
4. Public Awareness: Public awareness of the importance of pharmacovigilance and ADR reporting is still low in many regions. Increased education efforts are necessary to encourage patients and the general public to report ADRs.

4. Opportunities for Improvement

1. Regional Cooperation and Data Sharing: The EAEU provides a framework for enhanced regional cooperation. Expanding data sharing across borders and harmonizing pharmacovigilance regulations could lead to more efficient detection of safety signals.
2. Digitalization: Implementing digital platforms for ADR reporting can significantly improve data collection and analysis. The use of mobile apps and electronic health records (EHRs) can help streamline the reporting process and improve the quality of pharmacovigilance data (Zhdanova & Dmitriev, 2019).
3. Education and Training: Expanding education and training programs for healthcare professionals and patients is critical to improving ADR reporting rates. Public awareness campaigns can also help increase the overall effectiveness of pharmacovigilance systems.
4. International Collaboration: Continued collaboration with international organizations like the WHO, EMA, and the International Society of Pharmacovigilance (ISoP) can provide technical support and facilitate knowledge transfer.

5. Conclusion

The pharmacovigilance landscape in the CIS, EAEU, Georgia, and Ukraine is evolving rapidly, with many countries adopting international standards and harmonizing their regulatory frameworks. However, challenges such as underreporting, resource limitations, and regulatory discrepancies remain. By enhancing regional cooperation, improving digital infrastructure, and investing in education and training, these countries can strengthen their pharmacovigilance systems and improve drug safety for their populations.

References

• Gritsenko, I., et al. (2020). Pharmacovigilance in Ukraine: From Regulatory Framework to Practical Implementation. Journal of Drug Safety, 43(4), 423-430.
• Kordyukov, D., et al. (2020). Challenges in Pharmacovigilance in the CIS and EAEU. Pharmacology & Therapeutics, 44(2), 119-125.
• Kornienko, N., et al. (2018). The Development of Pharmacovigilance in Belarus: Current Status and Future Prospects. Pharmacology & Therapeutics, 45(2), 156-161.
• Kvaratskhelia, L., et al. (2019). The Role of the Georgian National Regulatory Authority in Pharmacovigilance. Georgian Medical News, 289, 43-47.
• Muradov, R., & Alakbarov, R. (2017). Overview of Pharmacovigilance in Azerbaijan: Current Status and Prospects. Azerbaijan Medical Journal, 71(2), 123-129.
• Roszdravnadzor. (2010). Federal Law No. 61-FZ on the Circulation of Medicines. Russian Federation.
• Sulaimanov, S., et al. (2020). The Role of Kazakhstan in the EAEU Pharmacovigilance System. Kazakh Pharmaceutical Journal, 35(3), 134-139.
• WHO. (2002). Pharmacovigilance: A Guide for Setting Up a National System. World Health Organization.